Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(5 sites)

United States

UCLA DGSOM, UCLA Health, UCLA Semel Institute, Los Angeles, California

University of Miami, Miller School of Medicine; Jackson Behavioral Health Hospital, Miami, Florida

Grady Behavioral Health Center, -Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia

Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland

Manhattan Psychiatric Center, The Nathan Kline Institute for Psychiatric Research, New York, New York